Last reviewed · How we verify

midazolam,fentanyl,etomidate,Cisatracurium besylate

First Affiliated Hospital Xi'an Jiaotong University · FDA-approved active Small molecule

This is a combination of four anesthetic and neuromuscular blocking agents used together for induction and maintenance of general anesthesia with paralysis.

This is a combination of four anesthetic and neuromuscular blocking agents used together for induction and maintenance of general anesthesia with paralysis. Used for Induction and maintenance of general anesthesia, Neuromuscular blockade during surgical procedures.

At a glance

Generic namemidazolam,fentanyl,etomidate,Cisatracurium besylate
SponsorFirst Affiliated Hospital Xi'an Jiaotong University
Drug classAnesthetic combination (benzodiazepine, opioid, hypnotic, neuromuscular blocker)
TargetGABA-A receptor (midazolam, etomidate), mu opioid receptor (fentanyl), nicotinic acetylcholine receptor at neuromuscular junction (cisatracurium)
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Midazolam is a benzodiazepine that enhances GABA-A receptor signaling for sedation; fentanyl is an opioid mu-receptor agonist for analgesia and sedation; etomidate is a non-barbiturate hypnotic that modulates GABA-A receptors for rapid induction; and cisatracurium besylate is a non-depolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the neuromuscular junction to produce paralysis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: